Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
News
Testing, Risk Factors & Considerations of Treatment: Nilotinib & Dasatinib
Publish date:
March 25, 2016
References
E-mail:
kalaycm@ccf.org
Pages
« first
1
2
Recommended Reading
Cardiovascular risk assessment required with use of TKIs for CML
MDedge Hematology and Oncology
KIR2DL5B genotype predicts outcome in chronic phase–CML
MDedge Hematology and Oncology
Novel test detects low levels of residual CML
MDedge Hematology and Oncology
Ponatinib effective in chronic phase CML regardless of baseline mutation status
MDedge Hematology and Oncology
Starting all CML patients on imatinib could cut costs, team says
MDedge Hematology and Oncology
Germline mutations linked to hematologic malignancies
MDedge Hematology and Oncology
Pinpointing the cells that cause CML relapse
MDedge Hematology and Oncology
New assay detects persistent CML better, team says
MDedge Hematology and Oncology
Generic imatinib launched with savings program
MDedge Hematology and Oncology
Potential new alternative in CML when TKI therapy fails
MDedge Hematology and Oncology
CML
All Specialties
